Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2025 04:22 ET | Source: Research and Markets

Addiction Disorders Drugs Market Analysis and Forecast to 2030: A $39.5 Billion Opportunity Led by Pfizer, Johnson & Johnson, and Indivior

Dublin, June 02, 2025 (GLOBE NEWSWIRE) -- The "Addiction Disorders Drugs Market by Indication, Product Type, Route of Administration, Dosage Form, Distribution Channel, End User - Global Forecast to...
May 08, 2023 09:18 ET | Source: Research and Markets

Global Opioid Induced Constipation Market Report 2023: Surging Availability of Diversified Treatments Bolsters Growth

Dublin, May 08, 2023 (GLOBE NEWSWIRE) -- The "Global Opioid Induced Constipation Market by Active Ingredients, Drug Class, Mode of Administration, Distribution Channel - Cumulative Impact of High...
April 14, 2023 06:58 ET | Source: Research and Markets

U.S. Opioid Induced Constipation Market Report 2023: Presence of Diversified Treatments for Opioid-Induced Constipation Bolsters Growth

Dublin, April 14, 2023 (GLOBE NEWSWIRE) -- The "Opioid Induced Constipation Market Research Report by Active Ingredients, Drug Class, Mode of Administration, Distribution Channel - United States...
May 24, 2022 06:49 ET | Source: Research and Markets

Global Global Suboxone Market Analysis/Forecast Report 2022-2030: Increasing Product Launches is Expected to Drive Growth

Dublin, May 24, 2022 (GLOBE NEWSWIRE) -- The "Global Suboxone Market by Type, Formulation, Distribution Channel, and Region - Size, Share, Outlook, and Opportunity Analysis, 2022-2030" report has...
October 09, 2018 08:00 ET | Source: BioCorRx Inc

BioCorRx, Inc. Announces Preliminary Agreement with VDM Biochemicals to Develop and Commercialize Patented Opioid Antagonist VDM-001

ANAHEIM, CA, Oct. 09, 2018 (GLOBE NEWSWIRE) -- VDM-001 represents potential alternative to naloxone for overdose reversal; Potential to reduce cravings from substance use disorder via...
April 22, 2014 07:41 ET | Source: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology

NORTHVALE, N.J., April 22, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the issuance of U.S. Patent No. 8,703,186 titled...
March 05, 2014 07:30 ET | Source: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200

NORTHVALE, N.J., March 5, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated...
February 18, 2014 07:00 ET | Source: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201

NORTHVALE, N.J., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today successful results from a pilot bioequivalence study...